Bayer's Debt Forecast Shrinks as Analysts Rush to Reset Price Targets Higher
Published on 08/12/2026 at 03:51 | Redaktion boerse-global.de
The investment case for Bayer has quietly shifted shape over the past week. The Leverkusen-based conglomerate's second-quarter numbers, released on the morning of August 5, did more than just beat expectations — they forced a wholesale rethink of how quickly the company can repair its balance sheet. Net financial debt is now projected to land between €29 billion and €30 billion, a meaningful improvement on the €32–33 billion corridor previously guided. That revision, coupled with stronger operational results, triggered an immediate share price reaction and set off a flurry of analyst upgrades.
A coordinated wave of target hikes
Goldman Sachs now carries the most bullish view on the street, lifting its price target to €63.50 with a "Buy" rating — the highest mark among major institutions covering the stock. UBS followed closely behind at €62, also maintaining its "Buy" stance. Deutsche Bank Research settled on €60 with a "Buy" call, while JPMorgan reaffirmed "Overweight" with a €61 target. The DZ Bank had earlier raised its fair value from €54 to €60, keeping a "Kaufen" rating.
What stands out is the breadth of agreement. Targets spanning €50 to €62 from the other major houses, all with positive ratings, suggest a consensus that the shares remain undervalued relative to the latest fundamentals. The improved debt outlook is being read as a signal that management is getting a firmer grip on the balance sheet faster than the market had anticipated — a development that could compress the risk premium investors have long attached to the stock.
The numbers behind the reassessment
The catalyst for this coordinated move was a second quarter that delivered on multiple fronts. Revenue came in at €10.872 billion, up 2.2 percent on a currency- and portfolio-adjusted basis. Adjusted EBITDA rose 1.9 percent, an unexpected gain, with the agriculture division providing the standout performance through solid business momentum and cost reductions. The first half of 2026 showed a higher net result even as revenue dipped slightly, and management confirmed its full-year guidance.
Should investors sell immediately? Or is it worth buying Bayer?
Additional support came from Bayer's Indian subsidiary, which reported a stronger quarterly profit thanks to lower costs — a detail that added to the generally constructive tone surrounding the group's operations.
Where the stock stands now
The market has already absorbed much of this optimism. The shares have advanced 32.72 percent since the start of the year and a striking 88.71 percent over the past twelve months. At the most recent close of €49.12, the stock trades roughly 9.77 percent above its 50-day moving average of €44.75. The relative strength index sits at 58.7, a neutral-to-slightly-positive reading that suggests the rally has not become overheated.
That said, the stock has pulled back slightly from its early-July peak. The 52-week high of €53.86 remains 8.80 percent above current levels — a gap that looks increasingly bridgeable given the fresh batch of analyst targets. On the day the Q2 numbers were released, the shares moved sharply, though they have since drifted sideways. The most recent session saw the stock give up 0.37 percent to €48.97, leaving it about 9.08 percent below that July high.
The legal calendar still casts a shadow
For all the progress on the operational and financial fronts, the glyphosate litigation remains the unresolved variable in the valuation equation. A US court has again postponed the hearing to approve the multibillion-dollar Roundup settlement, with the new date set for September 14. The repeated delays underscore that this legal complex is far from closed, a factor analysts are keeping in their models even as they maintain their positive stance on the underlying business.
Until that hearing takes place without further postponement, investors are likely to focus on the operational momentum that has driven the recent wave of target hikes. Should the September date hold, it could chip away at the uncertainty surrounding the glyphosate overhang — a scenario several analysts have already flagged as a potential catalyst in the months ahead. For now, the picture is one of improving fundamentals, a clearer deleveraging path, and a legal overhang that refuses to fully clear.
Ad
Bayer Stock: New Analysis - 12 August
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
